The country's trade outlook is entering a more challenging phase in the second quarter of 2026, with mounting external uncertainties expected to weigh on export performance.

Speaking at the Ministry of Industry and Trade’s regular press briefing on April 9, Tran Thanh Hai, deputy director general of the Agency of Foreign Trade, pointed to three major challenges shaping the near-term outlook.

He noted that global consumption is weakening as inflationary pressures continue to erode purchasing power, despite easing geopolitical tensions in the Middle East. This shift in consumer behaviour is expected to reduce import demand in key markets, directly affecting Vietnam’s exports.

In addition, risks related to raw material supply, particularly oil, remain a concern. Hai explained that oil is a critical input for multiple industries, including chemicals, plastics, and fertilisers, and any supply disruption could significantly increase production costs and compress profit margins.

Rising logistics costs are also re-emerging as a challenge. After a period of stability, transport expenses are increasing again, adding pressure on exporters, especially those operating in low-margin sectors.

However, Hai noted that the outlook is not entirely negative. If geopolitical conditions improve further and oil prices decline, input and logistics costs could ease, creating stronger conditions for export activities.

In this context, he stressed that business adaptability would be critical. “Enterprises need to flexibly adjust their market strategies, improve competitiveness, and make effective use of free trade agreements to sustain growth,” Hai said.

First-quarter data provides additional insight into Vietnam’s trade dynamics. Total import-export turnover reached nearly $250 billion, marking an increase of about 22 per cent on-year and signalling a strong recovery in trade activity.

At the same time, the trade balance recorded a deficit of approximately $3.6 billion, drawing attention as the country continues to target a full-year trade surplus.

Hai noted that this development should be viewed in context, explaining that the first quarter is typically not a period of strong trade surplus, as businesses tend to increase imports of raw materials and capital goods in preparation for production cycles later in the year.

"During the first quarter, even if there is a trade surplus, it is usually not significant. This is the period when enterprises import inputs and invest in equipment for new projects," he said.

This trend has been further reinforced by strong foreign direct investment inflows in 2025. As foreign-invested projects move into the implementation phase, demand for machinery, equipment, and production inputs has risen accordingly.

Data reflects this shift. Imports of electronic components increased by around half, while machinery, equipment, and spare parts rose by approximately 22 per cent. Imports of fuel and animal feed materials also recorded notable growth, all of which are essential inputs for production.

From this perspective, the trade deficit in the first quarter carries more of an investment nature than indicating structural imbalance. Hai underscored that the situation remains under control, despite the rapid pace of import growth.

Nevertheless, pressure is expected to build in the coming quarters. As import volumes rise, the ability of businesses to convert these inputs into exportable output will be crucial in determining whether the trade balance can return to surplus.

Vietnam’s trade performance in 2026 is therefore best understood as being in a transition phase, where short-term challenges coexist with medium-term opportunities driven by overseas funding and industrial expansion.

The venture is structured through a partnership and franchise agreement with Sodiaal Group (France), the owner of the Candia brand, thereby integrating European production and quality standards.

The Be Milk manufacturing plant will be developed in two phases with key highlight of the application of advanced European-standard technologies, supported by a strong network of international partners, including Sodiaal Group (France), IPEM Group (France), Tetra Pak (Sweden), and Takenaka Corporation (Japan).

According to Philippe Phan Van Ho, CEO of Swiss Asia Partner SA, selecting an investment location is not solely based on market potential, but also on the ability to meet long-term operational standards.

“Tay Ninh offers clear development potential in food processing, while Prodezi Industrial Park provides a suitable platform for us to execute the venture with efficiency, stability, and sustainability,” said Ho.

This alignment is reflected in the project’s ability to integrate seamlessly into the ESG-oriented infrastructure of Prodezi Industrial Park.

Wastewater systems are designed to meet environmental standards before connection to centralized treatment facilities, while energy efficiency and resource optimization solutions are embedded to support long-term operational performance. Furthermore, Prodezi’s industrial symbiosis model enables integration with related manufacturing activities, fostering a circular and sustainable production ecosystem.

Truong Khac Nguyen Minh, deputy general director of Prodezi Long An, stated that from the outset, Prodezi has pursued an eco-centric industrial park model, with infrastructure development aligned to environmental, social, and governance standards and industrial symbiosis principles.

“This approach has demonstrated strong compatibility with the requirements of international investors. Swiss Asia Partner SA’s decision to implement its venture at Prodezi is a positive signal, underscoring the broader investment potential of Tay Ninh. Looking ahead, we will continue to enhance our sustainable industrial ecosystem to better meet global investor standards and expand partnerships with international stakeholders,” Minh said.

Once operational, the Be Milk plant is expected to enhance Vietnam’s domestic dairy processing capacity through the transfer of European technologies and quality management practices. It will also strengthen value chain linkages from raw materials to distribution.

At the provincial level, the initiative is anticipated to generate employment, contribute to fiscal revenues, and add a high value-added manufacturing component aligned with Tay Ninh’s strategy to entice high-quality FDI and encourage industrial development.

The event takes place as Tay Ninh continues to strengthen its position as a leading investment destination in Southern Vietnam.

In 2025, the province ranked among the top 10 most attractive localities for large-scale enterprises, with newly registered and adjusted foreign direct investment (FDI) totalling $1.7 billion.

This strong performance is underpinned by ample industrial land availability, continuously improving regional connectivity, and a strategic focus on high value-added manufacturing industries.

At the same time, global FDI flows are increasingly shifting towards projects aligned with Environmental, Social, and Governance (ESG) standards. Tay Ninh’s well-prepared investment infrastructure positions the province to effectively capture this trend and enhance its competitive advantage.

Vietnam’s dairy sector continues to demonstrate robust growth. According to IMARC Group, the country’s dairy market is projected to reach $13.37 billion by 2033, with a compound annual growth rate of 9.5 per cent over 2025-2033.

Amid rising domestic demand and constrained local supply, the dairy processing industry presents significant opportunities for technologically advanced, internationally standardised projects such as Be Milk.

Prodezi Long An JSC, established in April 2016, with main business in real estate, with notable projects including the 400-hectare Prodezi Industrial Park with investment capital of more than VND 4,600 billion ($176 million) and the 100-hectare LA Home Township, launched in early 2024.

Swiss Asia Partner SA is an international investment and financial advisory group headquartered in Lausanne (Switzerland), with an extensive operational network across Europe, Southeast Asia, and the Middle East.

As part of its expansion strategy in Southeast Asia, Swiss Asia Partner SA currently acts as the market development representative and franchisee for the Candia milk and Yoplait yogurt brands of Sodiaal Group (France) - one of Europe's largest dairy groups and a Top 20 global dairy enterprise.

Sodiaal operates under an agricultural cooperative model with a network of over 8,000 member farms, running approximately 70 production facilities across multiple countries, and achieving a consolidated revenue of around around $7.58 billion in 2025.

Sodiaal's ecosystem encompasses a comprehensive value chain, from raw milk production and industrial processing to brand development and international product distribution. Within this ecosystem, Candia stands as one of Sodiaal's flagship brands and is recognised as the leading UHT milk brand in France, currently available in over 60 countries.

Furthermore, Sodiaal also owns Yoplait, one of the world's largest yogurt brands, with a well-established international distribution network across more than 50 countries worldwide.

The significant funding will enable the GEF to bolster investment in nature-positive development, helping developing countries address their most urgent priorities and generate global environmental benefits that help people as well as ecosystems.

Further pledges in support of a robust and ambitious four-year financing round are expected by the GEF Council meeting at the end of May, when the final replenishment package will be approved.

Read the full press release in English, French, or Spanish

"This replenishment sends a clear message: the world is not giving up on nature even in a time of competing priorities. Our donor countries have risen to the challenge and made bold commitments towards a more positive future for the planet. The coming four years of the GEF-9 cycle will reflect this high-ambition push to achieve the 2030 environmental goals," said Claude Gascon, Interim CEO and Chairperson of the GEF.

The GEF-9 investment cycle will cover the period from July 2026 to June 2030. Four overarching priorities will define the ambition and approach for the GEF over the next four years:

• Integration and Integrated Programs
• Blended Finance
• Whole-of-Government and Whole-of-Society Approaches
• Robust Funding for LDCs and SIDS, and a Significant Increase in Support to IPLCs

The 71st GEF Council meeting will be held in Samarkand, Uzbekistan from May 31 to June 3, 2026. The meeting will take place in advance of the Eighth GEF Assembly, when individual country pledges will be publicly announced.

For more information, visit: www.thegef.org

The AI-powered platform, which has provided more than $500 million in funding to online sellers, is known for its pioneering "AI CFO" technology – a real-time financial intelligence engine designed to help businesses plan, forecast, and scale with confidence. What sets the AI CFO apart is its ability to analyze a business in seconds and translate complex financial data into clear, actionable funding pathways.

By adding Temu to the platforms it supports, 8fig is expanding access to growth capital for a broader range of e-commerce sellers across the United States and Canada. Businesses operating on major marketplaces and storefront platforms can now access revenue-based financing and lump-sum financing through the platform.

Small businesses can apply for funding directly by submitting basic business details and securely connecting their bank account via open banking to receive fast assessments and financing decisions.

The AI CFO doesn't just present a single offer; it allows business owners to tailor their funding plan by adjusting amounts, timelines and cash flow structure to match how their business operates. This level of flexibility positions 8fig as more than a traditional funding source, but an active partner in business growth.

This evolution positions 8fig as one of the most adaptive and intelligent capital platforms in the market, combining instant insight, flexible planning and streamlined access to funding from $10,000 to $2 million.

"8fig was built to put sophisticated financial intelligence in the hands of everyday business owners," said Yaron Shapira, Co-Founder and CEO of 8fig.

"The AI CFO can understand a business in seconds, recommend a growth pathway and, most importantly, give the customer full control to shape the funding around their cash flow. Expanding beyond e-commerce means thousands more SMEs can now benefit from this technology."

The expansion follows 8fig's acquisition by Bizcap and its US affiliate NewCo Capital Group — a move that brought 8fig into one of the world's leading fintech ecosystems for non-bank funding. The partnership strengthens 8fig's ability to deliver capital with more speed, reach and operational firepower.

"8fig represents the future of intelligent business funding," said Bizcap's Global Co-Founder and Co-CEO Albert Gahfi.

"By combining the AI CFO's real-time financial intelligence with Bizcap's global scale, we're unlocking a new generation of products that meet the real-world needs of SMEs – online or offline."

8fig will continue to operate under its existing brand and leadership as it accelerates its roadmap, expands into new industries, and brings AI-driven growth tools to a wider universe of small businesses.

If you're an e-commerce business seeking fast, flexible funding, you can apply here. If you're interested in becoming a partner, 8fig is now accepting applications to become a partner.

For more information, visit bizcap.com.au

The DB-1303-O-3001 trial is a randomized, controlled, open-label, multicenter Phase III clinical trial conducted in China. It aims to evaluate the efficacy and safety of trastuzumab pamirtecan compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and taxane chemotherapy. As assessed by the Independent Data Monitoring Committee (IDMC), the trial has met its primary endpoint of statistically significant improvement of progression-free survival (PFS, assessed by Blinded Independent Central Review, BICR) for trastuzumab pamirtecan compared to T-DM1 at a pre-specified interim analysis.

Dr. Hua Mu, Global Chief Medical Officer of DualityBio, stated: "China has over 350,000 new breast cancer cases annually [1], representing a high incidence rate and ranking as the second most common cancer among Chinese women. We are delighted to see that DB-1303/T-Pam has achieved a milestone in its commercialization progress, demonstrating its potential to provide an effective new treatment option for breast cancer patients. In the China market, we have entered into a collaboration with 3SBio to jointly advance the commercialization of multiple indications of DB-1303/T-Pam in Chinese mainland, Hong Kong and Macao. Globally, we will continue to deepen our global strategic partnership with BioNTech to further drive the global development of this product. DB-1303/T-Pam is a globally co-developed new drug with strong strategic partners in both China and global markets. We will work closely together to accelerate the product's marketing approval process, maximize its global clinical value, present more treatment options to patients worldwide."

For more information, please visit www.dualitybiologics.com

The approval of TLX101-Px will fulfil a significant unmet medical need for the characterization of recurrent or progressive glioma from treatment related changes in both adult and pediatric patients^[5]. Neuroimaging of glioma with ¹⁸F-FET is already broadly recommended in international clinical practice guidelines – including NCCN Guidelines®^[6] – and TLX101-Px has been granted Orphan Drug^[7] and Fast Track^[8] designations by the FDA.

"There remains a critical unmet need in improving our ability to image residual glioma after treatment," said Thomas Hope, MD, Vice Chair, Department of Radiology and Biomedical Imaging, University of California, San Francisco (UCSF). "We have worked with Telix for the last three years to help leverage our clinical data to help make FET-PET^[9] available to patients in the United States."

Patrick Wen, MD, E. Antonio Chiocca, MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, added, "Distinguishing tumor progression from treatment-related change remains one of the most challenging aspects of glioma care. PET imaging with ¹⁸F-FET is an important tool in clinical practice worldwide, and the FDA's acceptance of this application is a meaningful step toward broader access for patients and clinicians in the United States."

Kevin Richardson, CEO, Telix Precision Medicine, added, "The FDA's acceptance of our NDA resubmission is an important milestone for Telix. We appreciate the FDA's constructive engagement and look forward to working closely with the Agency to urgently obtain approval and then bring this product to market for the benefit of patients."

Telix's FY 2026 financial guidance does not include any revenue contribution from TLX101-Px.

The company intends to offer 7 million shares at an indicative price range of KRW 12,400 to KRW 14,800 per share, implying a total offering size of approximately KRW 86.8 billion to KRW 103.6 billion. STRADVISION previously received preliminary approval from the Korea Exchange (KRX) on April 2 and will proceed with institutional book-building followed by a public offering ahead of its KOSDAQ listing. KB Securities will serve as the lead underwriter.

STRADVISION develops AI-based vision perception software for automotive applications. Its flagship solution, SVNet, has been adopted in mass production programs with global automotive OEMs, supporting the company's expanding footprint in the global mobility market.

SVNet is a camera-based perception solution that processes visual data in real time to accurately detect and recognize road objects, including pedestrians, vehicles, and lane markings. It serves as a core enabling technology for advanced driver assistance systems (ADAS) and autonomous driving. Built on a lightweight architecture, SVNet delivers reliable performance even in resource-constrained environments while maintaining compatibility across a broad range of hardware platforms.

In addition, STRADVISION has developed its proprietary integrated data pipeline, SVDataFlow, which automates key data processing tasks such as auto-labeling. This enables faster model development cycles while enhancing data-driven performance improvements and responsiveness to customer deployment requirements.

Leveraging technology designed to meet global vehicle safety assessment frameworks such as EURONCAP and regulatory requirements, including FMVSS, STRADVISION's solutions have been deployed across multiple OEM production programs. The company's software is compatible with more than 30 hardware platforms, further expanding its addressable market.

STRADVISION has surpassed 5 million cumulative vehicle deployments worldwide through its partnerships with global OEMs and has secured more than 1,000 patents globally, reinforcing its core Vision AI capabilities and technological barriers to entry.

The company has demonstrated strong growth, achieving a compound annual revenue growth rate (CAGR) of approximately 60% from 2023 to 2025. As adoption of Level 2 and higher ADAS features continues to accelerate, demand for STRADVISION's solutions is expected to grow in tandem with broader market expansion.

"Through mass production programs with global OEMs, we have validated our technology and built a solid foundation for sustainable growth, supported by our strong R&D capabilities and talent," said Junhwan Kim, CEO of STRADVISION.

"We aim to expand beyond Level 2 ADAS into Level 3 and Level 4 autonomous driving through continuous advancements in Vision AI and multi-vision technologies. In addition, we plan to extend our business beyond automotive into new domains including smart infrastructure, special-purpose vehicles, and robotics," he added.

www.stradvision.com

This year's event focused on reviewing the five-year progress of Kia's 'Total Transformation' initiative, following the company's brand relaunch in 2021. Kia also outlined its mid- to long-term growth roadmap across all business sectors.

"Building on the achievements of innovation across all areas over the past five years —including brand, EVs, PBVs, and ESG — EVs, HEVs, autonomous driving, and robotics will serve as key drivers for Kia's fastest growth to date. Even amid the evolving global environment, Kia will proactively respond to changing market conditions through differentiated strategies." – Ho Sung Song, President and CEO of Kia Corporation.

2030 Mid- to Long-Term Business Strategy

Kia aims to pursue a strategy to accelerate exponential growth, targeting global sales of 4.13 million units by 2030 with a 4.5 percent market share. This compares with a sales goal of 3.35 million units with a 3.8 percent market share in 2026.

Kia places customers at the centre of its business strategy and, over the mid- to long-term, the company intends to expand its mobility ecosystem with a strategic focus on PBVs, autonomous driving, and robotics, connecting people and infrastructure to drive enhanced value creation for both customers and wider society.

Overview of Key Announcements at Kia 2026 CEO Investor Day

For more information, visit the Kia Global Newsroom.

According to Atradius Senior Economist Theo Smid, "Our insolvency forecast has deteriorated due to the persistence of adverse economic conditions, including Covid‑related tax debts, rising input costs and ongoing trade tensions. The crisis in the Middle East, together with the associated increase in energy prices, adds to existing pressures. The impact on businesses will depend largely on the length of the conflict."

Atradius' baseline scenario assumes that the current closure of the Strait of Hormuz will begin to normalise from May, with only limited damage to Gulf infrastructure. If the disruption lasts longer, the insolvency projections would need to be revised.

Looking further ahead, the outlook improves in 2027, when insolvencies are projected to decline by 6% as inflation recedes, energy markets normalise and central banks regain room to reduce rates.

Regional outlook

In Europe, Atradius expects the highest rise in Switzerland, Italy and Portugal, while Ireland, Denmark, Norway and the Netherlands are set for decreases. Across the eurozone, companies continue to operate under substantial pressure in 2026. Higher energy prices, driven by disruptions in gas markets linked to the conflict in the Middle East, are feeding through to broader inflation and weighing on margins.

North America remains divided. In the United States, insolvencies are forecast to rise by 8% in 2026. The economic climate remains challenging for companies, with high trade tariffs and increased policy uncertainty continuing to weigh on the operating environment. In contrast, Canada is expected to see a decline in insolvencies as filings continue to normalise following the sharp rise in 2024.

In Asia‑Pacific, most monitored markets are set for decreases as insolvencies begin to retreat from historically high levels. New Zealand and Hong Kong show the strongest downward adjustments, while Australia, Japan and South Korea are likely to normalise more slowly.

For more detailed forecasts by country and region, access the full Atradius Insolvency Outlook.

More information at https://group.atradius.com.

ONC-841 is the world's first and only clinical stage anti-SIGLEC 10 antibody. The drug was initially developed, and is in a Phase 2 trial, for patients with solid tumors. New preclinical research by OncoC4 has revealed ONC-841's novel activity in normalizing microglia's function in clearance of pathogenic protein aggregates in the brain (1, 2). Benefitting from safety data from the oncology study, the new Phase 1/2 AD clinical trial received accelerated clearance to test the safety and clinical activity of the product for AD treatment.

The first study participant was successfully dosed at Xuanwu Hospital of Capital Medical University in China. The Principal Investigators for the clinical study are Professor Yi Tang and Professor Cuibai Wei at the Xuanwu Hospital.

"Extending our clinical study from cancer to AD showcases OncoC4's research engine and Xuanwu Hospital's infrastructure as the world's eminent AD research center. We are extremely grateful to our colleagues at Xuanwu for the collaboration, " said Dr. Yang Liu, CEO and Chief Scientific Officer.

"We are extremely excited to collaborate with OncoC4 to explore the potential of targeting SIGLEC 10, the novel checkpoints of AD pathogenesis, to bring clinical benefit for patients with this devastating illness", added Professor Yi Tang, Executive Vice President and Principal investigator.

More information: www.oncoc4.com.

Strategic Alliance: By Leveraging JW's Strengths in R&D and Commercialization in South Korea, Gan & Lee Will Establish a Strong Commercial Footprint in South Korea's High-Potential Metabolic Disease Market

Under the terms of the agreement, JW Pharmaceutical will be granted the exclusive rights to develop and commercialize Bofanglutide Injection in South Korea. Gan & Lee Pharmaceuticals will receive a one-time, non-refundable upfront payment of USD 5 million. Additionally, Gan & Lee is eligible to receive milestone payments totaling USD 76.1 million, contingent upon research and development progress, regulatory approvals, and commercialization achievements. Following the product's commercial launch, Gan & Lee will also receive tiered royalties based on net sales. The total potential transaction value reaches up to USD 81.1 million (excluding royalties).

This collaboration marks the third overseas out-licensing deal for Gan & Lee's Bofanglutide Injection, following previous partnerships in Latin America and India. According to data from Grand View Research, the GLP-1RA market in the Asia-Pacific region reached USD 5.47 billion in 2025 and is projected to grow to USD 16.95 billion by 2033, representing a compound annual growth rate (CAGR) of 14% [1], making it one of the fastest-growing regions globally. Currently, the treatment penetration rate of GLP-1 drugs remains extremely low, indicating massive growth potential. As a mature market in the Asia-Pacific region, South Korea's GLP-1RA market size reached USD 526 million in 2025 and is expected to increase to USD 1.6 billion by 2033 [2]. With its high acceptance of innovative drugs and strong patient purchasing power, the South Korean market has become a strategic foothold for multinational pharmaceutical companies entering East Asia. This collaboration marks another key step in the rapid global expansion of Gan & Lee's differentiated bi–weekly GLP–1RA, Bofanglutide.

Steady Progress in Global Phase III Clinical Trials; Bi-weekly Dosing Regimen Significantly Enhances Patient Compliance

Currently, as the world's first bi-weekly GLP-1RA to enter Phase III clinical research, Bofanglutide has advanced into the critical Phase III stage of its global development for three proposed indications: obesity/overweight, type 2 diabetes mellitus (T2DM), and obstructive sleep apnea (OSA). Existing clinical data demonstrate that Bofanglutide can effectively reduce body weight and blood glucose levels while comprehensively improving other metabolic parameters, yielding overall metabolic benefits. Its safety and tolerability profiles are consistent with other GLP-1RA class therapies. The bi-weekly dosing regimen further reduces the annual number of injections by 50% compared to mainstream once-weekly GLP-1RAs. This is anticipated to substantially boost patient adherence, offering a more convenient treatment option for the long-term, effective management of metabolic diseases.

As the global burden of metabolic diseases continues to rise, GLP-1 therapies are encountering tremendous market opportunities. South Korea, as one of the world's key pharmaceutical markets, exhibits a robust demand for innovative diabetes and weight-loss therapies. This collaboration will effectively address the clinical and commercial needs of the South Korean market for highly efficacious and convenient treatment regimens.

"This partnership with JW Pharmaceutical marks another pivotal step in the globalization strategy for Bofanglutide," stated Dr. Zhi Li, Chief Business Officer of Gan & Lee Pharmaceuticals. "GLP-1 therapies are reshaping the global treatment landscape for metabolic diseases. The convenience of Bofanglutide's bi-weekly dosing and its compelling clinical benefits will help address the unmet medical needs of South Korean patients. With over 80 years of experience, JW brings deep development and commercial expertise in metabolic diseases—a key factor in our decision to partner with JW."

Young-sub Shin, CEO of JW Pharmaceutical, commented: "This agreement represents a significant milestone in expanding our product portfolio within the rapidly growing therapeutic area of metabolic diseases, particularly diabetes and obesity. JW Pharmaceutical will leverage its established expertise in clinical development and regulatory execution, remaining committed to advancing the development and commercialization of Gan & Lee's Bofanglutide in South Korea, thereby bringing innovative treatment options to South Korean patients."

Proceeds will be strategically allocated to accelerate Oricell's global expansion and clinical development, while strengthening its technological capabilities and paving the way to capital market milestones.

As a frontrunner in cell therapy, OriCell is focused on engineering CAR-Ts with global clinical impact, having already secured confirmatory proof-of-concept (POC) data across multiple pipelines. By leveraging its proprietary triad: the Ori®Ab antibody screening and engineering platform, the Ori®Armoring functional enhancement platform, and the OnGo (Fast) rapid CMC manufacturing expertise, the company has built a differentiated portfolio that positions it at the vanguard of the global CAR-T race.

OriCell's lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma (HCC). Having successfully navigated investigator-initiated trials (IIT) and a registrational Phase 1 study, the program is now gearing up for pivotal trials. Clinical readouts have demonstrated a best-in-class efficacy and safety profile, with data highlighted at major forums including the ASCO Annual Meeting. With these promising results, Ori-C101 is positioned to become the first-in-class CAR-T therapy approved globally for HCC.

Beyond its lead asset, Oricell is aggressively advancing a diverse portfolio of next-generation modalities, including secreted, rapid-production, and in vivo CAR-T programs.

Dr. Huanfeng Yang, Chairman and CEO of Oricell Therapeutics, stated: "This financing is a testament to the global potential of our science and the dedication of our team. As we approach key inflection points in our clinical programs, our priority is clear: expedite the global development of our core assets and deepening our research into revolutionary technologies, including in vivo CAR-T and solid tumor CAR-T. We are committed to delivering transformative therapies that offer real hope to cancer patients worldwide, positioning Oricell as a dominant force in the global immunotherapy arena."

Shan Fu, Managing Partner at Vivo Capital, commented: "While cell therapy is undoubtedly the future of oncology, solid tumors remain the industry's toughest nut to crack. Oricell distinguishes itself not just through best-in-class clinical data for its GPC3 CAR-T, but also through a pragmatic and visionary roadmap for next-generation modalities like in vivo CAR-T. We have high conviction in their integrated 'Platform and Pipeline' strategy and believe they are poised to set the new standard of care in the field. Vivo Capital is eager to deploy our global network to accelerate Oricell's expansion into international markets."

William Hu, Managing Partner at Qiming Venture Partners, stated: "As an early investor that has stood with Oricell since the Pre-A round, we have witnessed every milestone of its journey—from technological exploration to pipeline realization, and from local innovation to global expansion. We look forward to Oricell leveraging breakthrough cell therapy solutions and stronger clinical data to define the next generation of cancer care, bringing hope to patients worldwide."

About Oricell Therapeutics

Oricell is a clinical-stage biotechnology company developing next-generation cell therapies to address unmet needs in oncology and immunology. Powered by a proprietary technology triad: Ori®Ab (antibody discovery), Ori®Armoring (T-cell enhancement), and OnGo CMC (rapid manufacturing), Oricell has advanced a diversified pipeline targeting both solid tumors and hematologic malignancies. This technical prowess and global strategy are exemplified by the development of another core candidate, OriCAR-017. Supported by compelling data from IIT in China, the program paved the way into global development, rapidly securing IND approvals from both China NMPA and US FDA, along with FDA Orphan Drug Designation (ODD) and Fast Track Designation (FTD). OriCAR-017 has demonstrated a favorable safety profile and robust efficacy in both IIT and registrational clinical trials, with data featured at leading global conferences including 2022 ASCO, 2022 EHA, 2024 ASCO, and published in top-tier academic journals The Lancet Haematology. These milestones underscore Oricell' capabilities in regulatory strategy, clinical development, and global execution, reflecting its commitment to transforming the future of cell therapy and delivering new hope to patients worldwide. For more information, please visit: www.oricell.com.

Forward-Looking Statements

This press release contains "forward-looking statements" which are not historical facts, but instead are predictions about future events based on the beliefs as well as assumptions made by and information currently available to the management of Oricell Therapeutics Holdings Limited ("the Company" or "Oricell"). The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date of this press release. The Company assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

The therapy, known as satri-cel (CT041), is the world's first CAR-T treatment specifically developed for solid tumors targeting Claudin18.2, a biomarker commonly found in gastric (stomach) and pancreatic cancers.

A New Era in Cancer Treatment

CAR-T therapy is a highly personalized treatment that uses a patient's own immune cells, reprogrammed to recognize and attack cancer cells with precision. Unlike traditional therapies, CAR-T cells can expand inside the body and continue to fight cancer over time.

While CAR-T has already transformed outcomes in blood cancers, this new therapy represents a major breakthrough in treating solid tumors, where effective options have historically been limited.

Promising Clinical Results

Clinical studies conducted in China have demonstrated encouraging outcomes for patients with advanced gastric and gastroesophageal cancers:

• Objective response rate (ORR): ~41%, significantly higher than standard treatments
• More than 10x improvement vs. conventional therapies in some comparisons
• Progression-free survival extended to ~4.7 months vs. ~1.7 months with standard care

These results have been presented at leading international conferences and published in top-tier medical journals, highlighting the global significance of this therapy.

Addressing a Major Unmet Need

Advanced gastric and pancreatic cancers remain among the most difficult cancers to treat, with limited effective options in later lines of therapy and poor survival outcomes.

This CAR-T therapy offers a new treatment pathway for patients who have exhausted conventional options.

Who May Benefit

This therapy may be suitable for patients who:

• Have advanced or metastatic gastric or gastroesophageal cancer
• Have received at least two prior lines of treatment
• Show Claudin18.2-positive tumors
• Meet clinical eligibility criteria

Each patient will undergo a detailed medical evaluation to determine suitability.

Looking Ahead

This therapy represents a milestone in oncology, opening the door for CAR-T treatments beyond blood cancers and into solid tumors.

Ongoing research is exploring broader applications, including earlier-stage treatment and additional tumor types.

Full article: https://jiahui.com/en/news/200

Highlights in Q1 include:

• Revenues from PCs grew by 15.6% YoY
• Revenues from gaming businesses grew by 25.4% YoY
• Revenues from commercial PCs ^[2] grew by 34.6% YoY

Acer's strategy to expand multiple business engines continued to gain momentum. Total revenues from businesses other than personal computers ^[3] and displays grew 29.2% YoY in Q1 and contributed 34.6% of the group's total revenues.

Acer's public subsidiaries have announced their March and preliminary Q1 revenues. In March, Acer Gaming successfully listed on the Taiwan Stock Exchange Innovation Board; while Acerpure expects to become listed on the Taipei Exchange (it is currently listed on the Taipei Exchange Emerging Stock Market) later this month. Among its businesses under incubation, Acer ITS Inc. revenue grew 113.8% in Q1 YoY.

The proposed transaction reflects strong confidence in Terra Quantum's differentiated quantum algorithms, software, quantum security, and hybrid quantum-classical solutions, as well as its commercial traction across multiple industries including defence, finance, pharmaceuticals, and logistics.

Upon completion of the transaction, the combined entity will be publicly listed, providing Terra Quantum with enhanced access to capital markets to support its next phase of growth, including product development, global expansion, and strategic acquisitions.

Strategic Rationale

The contemplated business combination is expected to enable Terra Quantum to:

• Accelerate the commercialization of ready to deploy quantum technologies
• Strengthen its balance sheet to support scaling operations globally
• Expand partnerships with enterprise and government customers
• Enhance visibility in the quantum computing sector

Management Commentary

"This milestone marks a significant step forward in Terra Quantum's mission to deliver practical quantum solutions on a global scale today," said Markus Pflitsch, Chairman & Chief Executive Officer of Terra Quantum AG. "Partnering with MLAC II would enable us to accelerate innovation, deepen customer engagement, and expand our global footprint."

Paul Grinberg, Chairman and Chief Executive Officer of MLAC II, added: "We believe Terra Quantum is uniquely positioned at the forefront of the quantum revolution which also has a management team with distinguished backgrounds in both science and the commercialisation of technology. This proposed transaction aligns with our strategy to partner with high-growth, category-defining technology companies that can create significant value."

Advisors

Cohen & Company Capital Markets, a division of Cohen & Company Securities, LLC, is serving as exclusive financial and capital markets advisor to Terra Quantum. Heussen Rechtsanwaltsgesellschaft mbH, together with Kellerhals Carrard, Winston & Strawn, LLP, and Niedermann Rechtsanwälte, are serving as legal counsel to Terra Quantum.

BTIG is serving as financial and capital markets advisor to MLAC II. Lowenstein Sandler LLP and Lenz & Staehelin are serving as legal counsel to MLAC II.

The project Green Export Incubation and Acceleration through Voluntary Sustainability Standards (VSS) – GEVA has played and continues to play an important bridging role, enabling enterprises to progressively integrate more deeply into global value chains.

Through one-on-one advisory support with experts, enterprises participating in GEVA have not only been assisted in reviewing and refining their business models and strengthening their green export orientation, but have also been progressively equipped with the knowledge, tools, and capabilities required to adapt to the increasingly demanding conditions of international markets.

This support has been designed practically, focusing on key areas such as business models, export operations, sustainability standards, packaging development, intellectual property, and branding. Such a process not only enhances enterprises’ internal capacities, but also contributes to fostering market-oriented thinking, strengthening personnel, and laying the groundwork for structured, long-term export strategies.

Building upon this foundation, GEVA’s international market connection activities have been implemented as a subsequent step and, at the same time, as a critical stage through which enterprises begin engaging directly with export markets. In this context, market connection is not regarded as an opportunistic starting point, but rather as a follow-on phase after enterprises have attained a certain degree of preparedness in terms of capacity, products, messaging, and development.

This approach enables enterprises to enter international markets in a more proactive manner, assess the suitability of their products, better understand the needs and expectations of international partners, and continue refining their products and strategies in pursuit of a sustainable and well-directed green export pathway.

Presence at international trade fairs

One of GEVA’s key interventions has been to support enterprises in participating in international trade fairs and exhibitions to create opportunities for direct engagement with buyers, product validation, and the expansion of partnership networks.

In September 2025, the project collaborated with the Vietnam Pepper and Spice Association (VPSA) to organise two booths at Vietnam Sourcing Expo 2025, a large-scale trade promotion event that brought together a significant number of international buyers and exporting enterprises. Through this activity, GEVA supported 17 enterprises within the venture network in rotating product displays and facilitated seven one-on-one B2B matching sessions with international partners. Nearly 70 prospective buyers were reached, generating encouraging indications of market demand and interest in Vietnamese agricultural and food products.

In January 2026 GEVA participated in the Taiwan Lunar New Year Fair 2026, establishing three booths and sponsoring five enterprises from the Incubation and Acceleration Programme in the coffee and spice sectors to showcase their products and connect with the market. Direct participation in a consumer fair enabled these enterprises to engage with local consumers and gain a clearer understanding of purchasing behaviour, consumer preferences, and market expectations.

In March 2026, GEVA continued this support by sponsoring three booths for selected spice enterprises to participate in the International Pepper and Spice Conference 2026 organised by VPSA. Through this event, participating enterprises were able not only to strengthen connections within the industry network, but also to engage directly with potential domestic and international buyers, stay informed of market trends, and gain insights into the strategic direction of the sector.

Online conferences

In parallel with in-person activities, GEVA organised four online green export market connection conferences focusing on key markets, namely Taiwan, Canada, the EU, and Japan. At each conference, speakers and participating partners– organisations with experience in market advisory and market connection and with networks of prospective buyers–shared information on import regulations, technical standards, consumer trends, and practical considerations for market entry. These exchanges contributed to supporting enterprises in accessing international markets in a more systematic manner.

Connect to the Japanese market – GEVA Project

Following the conferences, the list and product profiles of 23 enterprises participating in the Green Export Incubation and Acceleration Programme were consolidated and shared with market partners, buyers, and potential retail chains, thereby helping to encourage opportunities for commercial connection and cooperation.

Beyond the timeframe and scope of the funded project, GEVA and its partners remain committed to their role as a bridge for Vietnamese enterprises–from providing market intelligence and facilitating partner connections to offering strategic guidance on appropriate market entry approaches–thereby progressively reducing risks and enhancing the prospects for successful export activities.

Providing market intelligence

In parallel with the conferences, GEVA has directed its efforts towards developing market reports as a foundational knowledge resource for enterprises. Insights shared by experts and partners during the conferences will be systematised, analysed, and transformed into in-depth reports in collaboration with the speakers. These reports will cover consumer trends, import procedures, and sustainability standards in the agricultural sector.

These reports are expected to be published soon and will serve as practical reference tools for enterprises– particularly small and medium-sized enterprises–by enhancing their understanding of market conditions, enabling them to prepare more proactively, and supporting them in progressively meeting export requirements. The reports will contribute to mitigating risks and improving access to international markets.

Connect to the Canadian market – GEVA Project.

A green export ecosystem

The combination of strengthening internal capacities and facilitating market connections has created a comprehensive approach for enterprise support. Within this, direct exposure to export markets is regarded as an essential and decisive factor in the transition from being “ready” to being genuinely capable of exporting.

Through participation in trade fairs, engagement with buyers, and access to insights from experts and market connection organisations, enterprises can better understand actual market requirements–from product standards and consumer behaviour to partner expectations. These are dimensions that theoretical training alone cannot fully substitute.

Through this approach, GEVA is developing a practical support model that enables enterprises to “test, learn, and adjust” within real market environments, progressively refining both products and business strategies. This approach not only enhances export readiness and reduces risks, but also contributes to encouraging greener and more sustainable enterprise development, while fostering a green export support ecosystem aimed at increasing the value of Vietnamese agricultural products and strengthening Vietnam’s position in global markets.

GEVA showcases sustainable agricultural products at Vietnam International Sourcing Expo The GEVA project showcased sustainable agricultural products and took proactive steps to expand international business connections at the Vietnam International Sourcing Expo 2025.

Voluntary Sustainability Standards pave way for Vietnam’s agricultural exports A single rejected shipment can take years for an exporter to rebuild trust with international partners, and may even tarnish the reputation of an entire sector. By contrast, exporters that consistently meet required standards can benefit from “green lane” clearance, enjoying faster inspections and lower logistics costs.

GEVA a launchpad for Vietnam’s agricultural exports Green Export Acceleration through Voluntary Sustainability Standards (GEVA) is expected to become a pioneering model that empowers agricultural enterprises to integrate sustainability standards into their business strategies and drive green transformation.

According to the Board of Directors’ report at the AGM, VIB recorded a compound annual growth rate of 20–30 per cent across key metrics in 2017–2025, outperforming industry averages.

Annual growth reached 21 per cent in total assets (industry: 12 per cent), 23 per cent in retail credit (14 per cent), and 26 per cent in profit (23 per cent), while return on equity averaged 23 per cent, compared with 17 per cent for the sector.

In 2025, VIB focused resources on long-term strength by significantly increasing provisioning, strengthening capital and risk management, and investing heavily in technology, products and services across retail banking, corporate banking, and human capital.

These efforts laid a solid foundation for the next growth phase. Pre-tax profit reached $350.8 million, up 1 per cent on-year. As of December 31, 2025, total assets reached$21.38 billion, up 13 per cent on-year. Total credit outstanding reached $14.69 billion, up 18 per cent on-year. Customer deposits and valuable papers reached $12.69 billion, up 10 per cent on-year.

Retail banking a key growth driver

Retail banking continued to be VIB’s primary growth driver, with total outstanding retail loans reaching nearly $10.5 billion as of December 31, 2025, accounting for approximately 70 per cent of the bank’s total loan portfolio. Over 90 per cent of these loans are secured. In 2025, VIB joined the “million-card club,” with more than 1.1 million cards in circulation and total card spending exceeding $5 billion. Fee income from cards and retail services surpassed $76.9 million, contributing significantly to over $134.6 million in total non-interest income from the retail banking segment.

VIB is building a strong fee-based income foundation, reducing reliance on net interest margin. This strategic shift aligns with expanding into higher-income customer segments, enhancing the service ecosystem, and increasing customer lifetime value.

Retail credit outstanding. Source: AGM 2026

In 2025, VIB’s corporate banking segment shifted from traditional lending to delivering comprehensive financial solutions, including cash management, transaction banking, foreign exchange and capital markets, and trade finance. As a result, corporate lending grew by 58 per cent, CASA increased by 20 per cent, and fee income surged by 280 per cent, while asset quality remained tightly controlled–laying a solid foundation for sustainable long-term growth.

In 2025, 97 per cent of total individual customer transactions were conducted through digital channels. Digital transaction volume increased by 30 per cent on-year to nearly 680 million transactions, while total transaction value rose by 26 per cent to $176.92 billion.

The MyVIB application was recognised by International Finance Awards as the “Most Innovative AI Solution in Digital Banking 2025.”

In 2025, VIB maintained its leading position in Basel III implementation, with a Capital Adequacy Ratio of 12.2 per cent under the Standardised Approach, demonstrating the bank’s strong balance sheet resilience while supporting continued growth.

2026 business plan and strategic directions

The AGM approved the 2026 business plan proposed by the Board of Directors.

Credit growth may be adjusted subject to limits approved by the State Bank of Vietnam. Source: AGM 2026.

Building on the achievements over the 2017–2025 period and the solid foundations established, VIB has defined four strategic priorities for 2026, forming the basis for developing an innovative and intelligent business model and setting new standards for next-generation financial products and services in the VIB 3.0 phase (2027–2036).

VIB targets the full spectrum of individual customers–from Youth, Mass, and Mass Affluent to Affluent–while also expanding strongly into the household business and SME segments. Each segment is delivered deeply personalised financial experiences powered by data and AI.

At the same time, five product pillars are comprehensively upgraded: fully digital end-to-end lending; deposit solutions that optimise personal assets; card products that empower customers to actively choose and personalise their benefits; insurance and investment solutions offering comprehensive 360-degree protection; and payments and transactional banking that accompany customers throughout their spending journeys. VIB aims to become the market leader in cards within the next three years, positioning VIB cards as a mass-market payment tool.

In 2026, VIB will accelerate personalisation beyond the individual level to the broader customer ecosystem, elevate the overall standards of Privilege Banking experiences, and strengthen tailored solutions for business banking. On April 10, VIB will launch its Priority Banking segment, redefining privileges and delivering flexible financial solutions that empower customers.

VIB continues to focus on developing comprehensive solution packages across lending, funding, and transactional banking, standardised by segment. The bank is digitising end-to-end processes for serving corporate clients, while maintaining a prudent and intelligent risk appetite supported by early warning systems and industry-based monitoring.

VIB’s technology roadmap for 2026 is shaped by multiple initiatives aimed at gaining deeper customer insights, enabling more precise personalisation, and supporting real-time decision-making. Key projects include the T24 Core Banking system on AWS, providing a cloud-native infrastructure with enhanced scalability, continuous operations, and data readiness for large-scale real-time AI applications. Agentic AI enables faster credit decisions, real-time fraud detection, and large-scale personalised product recommendations. Salesforce CRM delivers a 360-degree customer view, enabling consistent and seamless customer service across both physical and digital channels.

VIB aims to double productivity for its current workforce of 10,000 employees, equivalent to the output of 20,000 employees, through the HAGT model, where H represents Human Intelligence, A represents Artificial Intelligence, G represents the General Navigation Map (GNM), and T represents Technology Tools.

GNM serves as a coordination system, ensuring that all initiatives–from the Board of Directors to individual employees–are structured under a unified logic of what needs to be done and how to execute it. This enables strategy to be translated into structured, trackable actions at every level. GNM has been developed at VIB over more than nine years as a proprietary framework, applied consistently across the organisation from strategy formulation to execution.

The new investment was committed by existing shareholders, backed by leading global investors, reinforcing conviction in ESR's strategy, platform, and growth momentum.

The capital will be deployed to fund growth initiatives across ESR's logistics real estate and data centres platforms. This builds on the significant progress achieved following ESR's privatisation in July 2025, as the Group advances its strategic transformation into a more focused business positioned for long-term growth.

In line with this strategy, since January 2025, ESR has realised more than US$2 billion in net proceeds through the divestment of non-core holdings and recapitalisation of balance sheet assets, simplifying the portfolio and recycling capital into core growth sectors.

Together, these developments have strengthened ESR's ability to scale its fund management and development platforms, while capitalising on long‑term structural tailwinds including e-commerce growth, supply chain reconfiguration, and accelerating digitalisation.

Phil Pearce, President of ESR, said, "ESR has entered its next phase of growth with a stronger capital base and a more focused platform. As global capital continues to shift toward APAC, investors are increasingly seeking managers with local depth, strategic clarity, and a proven ability to execute in an evolving market environment.

We are pleased to be deepening our partnership with leading global investors, who are not only shareholders, but also long-term capital partners across our platform. With a sharpened focus on logistics real estate and data centres, we are accelerating development and fundraising while driving sustained growth in leasing and capital deployment. Looking ahead, we remain focused on scaling our core business with discipline and delivering long-term value for our capital partners and customers."

ESR's growth strategy is centred on priority markets in Australia, Japan, and South Korea, while expanding opportunities across Greater China, India, and Southeast Asia. Reflecting the strength of its institutional relationships, ESR partners with 12 of the world's top 20 real estate Limited Partners and has raised an average of US$3.8 billion annually across its key sector mandates over the past five years.

In logistics real estate, demand continues to concentrate on modern, large‑scale, and well‑located logistics assets near consumption hubs and major population centres. Serving over 1,500 customers, ESR is advancing an approximately US$9 billion development pipeline to meet evolving customer needs while creating investment opportunities for capital partners.

Leveraging the scale and depth of its APAC platform, ESR's data centres business is differentiated by its ability to secure land and power early in the development cycle, supporting a pipeline of over 3 GW of capacity for phased development in key growth markets.

https://www.esr.com/

The issuer is solely responsible for the content of this announcement.

Jointly developed by Sino Land Company Limited (Stock Code: 0083.HK), Kerry Properties, K. Wah International, China Merchants Land, and MTR Corporation, La Mirabelle recorded sales of 522 units as of 7 April. Mr Victor Tin, Executive Director of Sino Land Company Limited, noted that buyers hailed from diverse markets, including the United Kingdom, Korea, India, and the Chinese Mainland. Approximately 80% were end users and 20% investors—evidence of robust ongoing demand.

Daryl Ng, Chairman of Sino Land Company Limited, commented, 'We are encouraged by the enthusiastic market response to La Mirabelle at LOHAS Park, a premier residential community in Tseung Kwan O, which has delivered HK$4.6 billion in sales in two weeks. Strong end-user participation, coupled with interest from international buyers, signals continued confidence in Hong Kong's residential market. We believe this momentum underscores Hong Kong's enduring appeal as a global city for living, working, and investment, bolstered by its world-class connectivity and established business ecosystem.'

Market observers anticipate sustained capital inflows into Chinese Mainland and Hong Kong. Renowned for its robust legal system, deep financial markets, and stable US dollar peg, Hong Kong remains a preferred destination for property investment. La Mirabelle's strong sales performance signals enduring appeal among both local and international buyers.

As a long-term investor and developer in Hong Kong, Sino Land is committed to sustainable development and responsible business practices as part of its long-term approach to delivering quality homes and communities. The Company maintains strong ESG performance and has been ranked among the Global Top 5% in the Real Estate Management & Development industry in the S&P Global Sustainability Yearbook 2026. Among more than 9,200 companies assessed worldwide, Sino Land is the only developer from Hong Kong to receive this recognition. This marks the company's fourth consecutive inclusion in the Yearbook and its first ranking in the Global Top 5%. The Company has also been recognised through CDP Climate Change A List inclusion, GRESB five-star ratings in both the Development and Standing Investment Benchmarks, and an AAA rating from MSCI.

The issuer is solely responsible for the content of this announcement.

The issuer is solely responsible for the content of this announcement.

For more information, please visit https://www.peakenergy.asia.

1. Kenanga Growth Fund ("KGF") – Best Equity Malaysia – Malaysia Provident Funds over 5 Years
2. Kenanga Growth Fund Series 2 MYR Class ("KGFS2") – Best Equity Malaysia Diversified – Malaysia Provident Funds over 3 Years
3. Kenanga Malaysian Inc Fund ("KMIF") – Best Equity Malaysia Diversified – Malaysia Provident Funds over 10 Years
4. Kenanga Managed Growth Fund ("KMGF") – Best Mixed Asset MYR Balanced Malaysia – Malaysia Provident Funds over 10 Years

The issuer is solely responsible for the content of this announcement.

The issuer is solely responsible for the content of this announcement.

For more information, please visit www.discovery.com.

The issuer is solely responsible for the content of this announcement.

Nuttaphong Kunakornwong, Chief Executive Officer of SC Asset Corporation Public Company Limited or SC, said that the fragile global economic environment has prompted the company to proactively adapt over the past two to three years. These efforts include organizational restructuring, financial discipline, expanding joint investment partnerships, and initiating new businesses in line with its risk diversification strategy. The company has gradually reshaped its business structure into a portfolio built around three business engines. These include Engine 1 Residential Property, Engine 2 Recurring Income Property, and Engine 3 New Businesses for a Better Future.

SC is also targeting to increase the profit contribution from Engine 2 and Engine 3 to more than 30 percent in order to drive the company's overall profit to reach a new high again by 2030, while ensuring that all businesses continue to create value for people and the planet.

In 2026, the company will implement a comprehensive rebrand, including a new logo and refreshed corporate identity, marking its first such transformation in 20 years. The move reinforces SC's position as "Beyond Residential," supported by a more flexible and diversified portfolio, enabling the company to engage more effectively with customers, employees, partners, investors, and stakeholders.

2026 Business Targets and Plans

• SC targets total revenue of THB 25.5 billion in 2026, representing 21% growth year-on-year, with a capital expenditure budget of THB 8 billion to drive all three business engines. The Interest-Bearing Debt to Equity ratio (IBD/E) is expected to decline to below 1.2 times.

• Engine 1: Residential Property, targeting sales of THB 27 billion, up approximately 33% from 2025, and transfers of THB 23 billion, with backlog of more than THB 18.5 billion as of end-2025, of which around 40% is expected to be recognized in 2026.

- Low-rise housing: Revitalizing of eight single-detached home series across 17 projects under a concept focused on deeply understanding life needs.
- Condominium: Launch of a new ultra-luxury branded residence and a new riverside project, with a combined value of THB 25.5 billion across two projects.

- Introduction of "GenSCription" (Living Subscription Program by SC), responding to the growing shift toward renting instead of homeownership among younger generations, increasing accessibility and flexibility in housing.

• Engine 2: Recurring Income Property, covering operations across hotels, warehouses, office buildings, and rental apartments in the U.S. The business targets revenue growth of around 70 percent to THB 2 billion.

- Expansion of hospitality portfolio by 450 rooms in key seaside destinations such as Pattaya and Phuket.
- Development of an additional 170,000 square meters of warehouse space in the Bangna–EEC zone.
- Investment in alternative energy businesses to support data center growth under SCX 360.

• Engine 3: New Businesses for a Better Future, covering after-sales services, digital platforms, and health related businesses. The company targets revenue of THB 400 million this year, representing growth of around 60 percent from 2025.

- After-sales services will expand from 150 projects to 260 projects, alongside the launch of LINTON, a concierge service designed for ultra luxury residents.
- SC has allocated an investment budget of THB 1 billion over the next three years to support the growth of this business segment.

• SC also introduced "SC Green Mark," a green building development standard encompassing environmental performance and residents' quality of life. The standard will be applied across all engines and projects to ensure sustainable growth aligned with long-term environmental responsibility.

• Sustainable business operations

- The company continues to operate in accordance with international sustainability assessment standards of FTSE Russell.
- SC is advancing its greenhouse gas reduction efforts in line with its five-year target of reducing 100,000 tons of carbon emissions from 2025 to 2030.
- The company is also introducing SC Green Mark, a green building development standard covering environmental performance and residents' quality of life, which will be applied across all engines and projects.

"Brands are like living things. They survive through evolution, and brands that fail to adapt will eventually become extinct. SC therefore continues to evolve. Rebranding and organizational reform are part of that evolution. A more flexible and diversified business portfolio will enable SC not only to survive but to grow sustainably in the highly volatile and challenging real estate industry, while creating greater value for people more broadly," Nuttaphong said.

The issuer is solely responsible for the content of this announcement.

• Climate action – Decarbonisation remains top priority. 8% decline in scope 1 and 2 emissions from companies on the Decarbonisation and Transition pathway
• Responsible consumption – Improvements in waste reduction, resource efficiency and circularity initiatives. 29% decrease in total waste generated and 95% total waste diverted from landfill
• Social inclusion – Ongoing investments in education, health and livelihoods. US$59m in community investments made
• Governance and transparency – Enhanced sustainability governance and disclosure as Jardines maintains portfolio oversight of sustainability across its portfolio. ESG ratings improvement reflect positive response on sustainability performance (S&P: 82nd percentile, ISS ESG: Prime)

Ben Keswick, Executive Chairman of Jardine Matheson said, "Sustainability is foundational to how we protect and enhance economic value and build long-term resilience across Jardine Matheson – it is an essential value that every business in our portfolio must commit to and that guides the investment decisions we make. We will continue to embed sustainability in our strategy and portfolio management decisions, with a clear focus on decarbonisation, by setting clear commitments, measuring progress against our roadmaps, and applying disciplined governance across our portfolio."

Decarbonisation is top priority
Contributing to a sustainable, low-carbon future is a strategic priority for Jardines. In 2025, the Group delivered an 8% reduction in total scope 1 and 2 emissions, reflecting steady progress across its diversified portfolio. This was supported by a continued shift away from fossil-fuel energy, with renewable energy accounting for 45% of total energy consumption, alongside an overall reduction in energy use.

Jardines' decarbonisation approach is structured around two pathways: a Decarbonisation Pathway, and a Transition Pathway for mining and energy businesses.

In 2025, Jardines' portfolio companies began formal reporting on climate risks and opportunities to their audit committees, following the integration of climate risks into existing ERM processes the prior year. Alongside, Jardines is also integrating sustainability factors into investment due diligence and decision-making, ensuring material sustainability-related aspects of an investment are considered as Jardines continues to unlock value creation for its stakeholders.

Looking forward
Looking ahead, Jardines will continue to embed sustainability as a core value driver across its portfolio by setting clear commitments and prioritising decarbonisation. The Group will continue to strengthen governance and incentives to drive accountability and deliver on scope 1 and 2 emissions reduction pathways.

To access the Sustainability Report 2025, please visit sustainability.jardines.com/2025/ or click here to download the PDF.

https://www.jardines.com

The issuer is solely responsible for the content of this announcement.